# EV-103 (NCT03288545)

> A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03288545
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: Astellas Pharma Global Development, Inc.
- Conditions: Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Urologic Neoplasms; Renal Pelvis Neoplasms; Urothelial Cancer; Ureteral Neoplasms; Urethral Neoplasms
- Interventions: enfortumab vedotin (EV); pembrolizumab; cisplatin; carboplatin; gemcitabine
- Enrollment: 348
- Primary outcome: Type, incidence, severity, seriousness, and relatedness of adverse events (Dose escalation and Expansion Parts 1 to 3 cohorts only)
- Primary outcome: Type, incidence, and severity of laboratory abnormalities (Dose escalation and Expansion Parts 1 to 3 cohorts only)
- Primary outcome: Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) (Cohort K only)
- Primary outcome: Pathological complete response (pCR) rate per central pathology review (MIBC cohorts only)

## Commentary we found

- X threads: 63
- Podcasts: 45
- YouTube: 41

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ev-103-nct03288545

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03288545", "email": "<work email>"}; the inbox owner confirms by the emailed link.